Transform. Accelerate. These are the apparent goals of a collaborative effort to fund and staff a non-profit that will work to alleviate bottlenecks in the pharmaceutical R&D process. Unveiled Sept. 18, TransCelerate BioPharma Inc. will strive to identify and solve common drug-development challenges, improve clinical trial quality and ultimately bring new products to market more quickly.
TransCelerate acting CEO Garry Neil, former corporate VP, science & technology, at Johnson & Johnson, said the primary issues...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?